Recombinant anti-IL-4Rα humanized monoclonal antibody (Sansheng Guojian)
- Generic Name
- Recombinant anti-IL-4Rα humanized monoclonal antibody (Sansheng Guojian)
A Study to Evaluate 611 in Patients with Chronic Rhinosinusitis with Nasal Polyps
- First Posted Date
- 2024-10-14
- Last Posted Date
- 2024-10-14
- Target Recruit Count
- 240
- Registration Number
- NCT06639295
- Locations
- 🇨🇳
Site 01, Beijing, Beijing, China
Evaluation of 611 in Combination With Topical Corticosteroid in Participants With Moderate to Severe Atopic Dermatitis
- Conditions
- Dermatitis, AtopicEczema, Atopic
- Interventions
- First Posted Date
- 2024-08-15
- Last Posted Date
- 2024-10-01
- Target Recruit Count
- 400
- Registration Number
- NCT06554847
- Locations
- 🇨🇳
Hangzhou First People's Hospital, Hangzhou, Zhejiang, China
🇨🇳Shanghai Dermatology Hospital, Shanghai, Shanghai, China
🇨🇳The First Affiliated Hospital of Ningbo University, Ningbo, Zhejiang, China
Evaluation of 611 in Chinese Children and Adolescents With Moderate to Severe Atopic Dermatitis
- Conditions
- Dermatitis, Atopic
- Interventions
- First Posted Date
- 2024-03-22
- Last Posted Date
- 2024-03-22
- Target Recruit Count
- 104
- Registration Number
- NCT06324812
Evaluation of 611(Recombinant Humanized Anti-interleukin-4 Receptor Alpha IgG4 Monoclonal Antibody) in Chinese Adults With Moderate to Severe Atopic Dermatitis
- First Posted Date
- 2023-12-15
- Last Posted Date
- 2024-02-01
- Target Recruit Count
- 510
- Registration Number
- NCT06173284
- Locations
- 🇨🇳
Peking University People's Hospital, Beijing, Beijing, China
🇨🇳Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
🇨🇳The Fourth Affiliated Hospital Zhejiang University School of Medicine, Jinhua, Zhejiang, China
A Study to Evaluate 611 in Patients With Chronic Rhinosinusitis With Nasal Polyps
- Conditions
- SinusitisNasal PolypsPolyps
- Interventions
- Drug: Placebo
- First Posted Date
- 2023-05-19
- Last Posted Date
- 2024-01-12
- Target Recruit Count
- 90
- Registration Number
- NCT05865496
- Locations
- 🇨🇳
Site 02, Xuzhou, Jiangsu, China
🇨🇳Site 01, Beijing, Beijing, China
🇨🇳Site 03, Beijing, Beijing, China
Evaluation of 611 in Chinese Adults With Moderate to Severe Atopic Dermatitis
- Conditions
- Dermatitis, Atopic
- Interventions
- First Posted Date
- 2022-09-16
- Last Posted Date
- 2024-02-01
- Target Recruit Count
- 93
- Registration Number
- NCT05544591
- Locations
- 🇨🇳
Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
🇨🇳Peking University People's Hospital, Beijing, Beijing, China
🇨🇳Dermatology Hospital of Southern Medical University, Guangzhou, Guangdong, China
Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers
- First Posted Date
- 2020-08-26
- Last Posted Date
- 2022-11-10
- Target Recruit Count
- 40
- Registration Number
- NCT04527718
- Locations
- 🇺🇸
Covance Dallas Clinical Research Unit, Dallas, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.